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between 40 and 80, were recruited by 40 diabetes clinics. A pilot
test-retest validity testing was performed on the same 10 respon-
dents following 2 weeks interval. Ten self-assessment items 
were developed for exploring preference on home glucometers;
3 items were developed for the following domains: needs for
better understanding on diabetes (yes/no); blood glucose self-
monitoring period (<6 months, >6 <18 months, >18 months <3
years, >3 <6 years, >6 years); access to diabetes clinics (regularly
scheduled—yes/no). The Pearson chi-square statistic for two-way
tables was used to test the association between variables; alpha
level of 0.05 was used in all analyses. RESULTS: Patients were
comparable for sex within each class of age (p = 0.670 / 40–
50 years; p = 0.152 / 50–60 years; p = 0.371 /60–70 years; p =
0.370 / 70–80 years). Unsatisﬁed (u) and satisﬁed (s) patients on
general information on diabetes respectively decreased and grew
with increasing age: 60.98% (u), 39.02% (s)/ 40–50 years; 52.14
% (u), 47.86% (s)/ 50–60 years; 45.77% (u), 54.23% (s)/ 60–70
years; 41.67% (u), 58.33% (s),/ 70–80 years (p = 0.05) without
correlating to SBGM period (p = 0.690). Frequency of accesses
to diabetes clinics increases with age from 40 to 80 (p = 0.004).
CONCLUSIONS: Patient perceived dissatisfaction with general
information on diabetes decreases with age and is independent
of SBGM period. Further studies have to be performed to eval-
uate if a better perceived knowledge of the disease can improve
adherence to the treatment and clinical outcomes.
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OBJECTIVES: To assess treatment satisfaction (TS) in a large
population of Type-2 diabetes subjects (T2DM) treated with
insulin glargine (GLAR). METHODS: The 24-week, multina-
tional AT.LANTUS study investigated TS with GLAR initiation
and titration (target FBG £5.5mmol/L) according to two algo-
rithms (Alg): Alg1 was physician based; Alg2 involved subject
self-titration. TS were assessed using the Diabetes Treatment 
Satisfaction Questionnaire status (DTSQs) and change (DTSQc).
Since blood glucose (BG) controls and stability (MODD, MAGE,
8-point BG proﬁles) improved signiﬁcantly, relationships with TS
were explored. RESULTS: TS was evaluated in a group of 
subjects from the eight countries in which the questionnaire was
validated, with 1289 subjects at baseline and 1023 subjects 
at endpoint. Mean baseline DTSQs scores were comparable
between Alg. (26.5 vs. 26.1) with signiﬁcant improvements at
endpoint (both +4.99; p < 0.001). Perceived hyperglycaemia sig-
niﬁcantly decreased (p < 0.001) with both Alg. TS evolution over
time (DTSQc) improved by +13.6 with both Alg. Perceived hypo-
glycaemia decreased in the DTSQc. There were signiﬁcant (p <
0.0001) correlations between fasting BG, mean 8-point BG and
evolution of TS scores and perceived hyperglycaemia. Evolution
of perceived hyperglycaemia was also associated with move-
ments towards BG stability (MAGE: p < 0.0001; MODD: p =
0.0004). A similar pattern of results was seen in the Type-1 pop-
ulation. CONCLUSIONS: This study provides one of the largest
assessments of TS to date and shows that aggressive titration of
GLAR is associated with signiﬁcantly improved TS. Self-titration
was associated with greater improvements in perceived hyper-
glycaemia versus physician-based titration. Perceived overall TS,
hyperglycaemia and hypoglycaemia at endpoint were all corre-
lated with movements towards BG control and stability, provid-
ing potential explanation as to why subjects feel better with
GLAR than their prior therapy.
EYE
PEY1
ANXIETY AND DEPRESSION IN WET AGE-RELATED
MACULAR DEGENERATION (ARMD)
Maurel F1, Hieke K2, Negrini C3, Priol G1, Berdeaux G4, Le Pen C1
1Aremis, Neuilly sur Seine, Hauts de Seine, France; 2Neos Health,
Binningen, Switzerland; 3PBE-Consulting,Verona, Italy; 4Alcon France
SA, Rueil-Malmaison, Hauts de Seine, France
OBJECTIVE: To study the relationship of ARMD severity to
anxiety and depression in three European countries: France,
Germany and Italy. METHODS: Patients with wet ARMD 
were included in a retrospective cross-sectional survey. Socio-
demographic and medical data were collected during a visit by
a retina specialist. Anxiety and depression were assessed with the
Hospital Anxiety and Depression Scale (HADS). Two thresholds
were used to dichotomize visual acuity (VA): 20/40 for the best
eye (BE) and 20/200 for the worst eye (WE). Comparisons with
general population matched on age and gender were possible for
the German patients (Hinz, 2004). Analysis of variance was per-
formed to estimate the effect of each eye adjusted on age, gender
and country. RESULTS: A total of 360 patients were included.
The patients (40% male) averaged 77 years of age and 2.3 years
of disease duration. VA was 0.49 LogMAR on the BE the day
of the visit. In the German population, ARMD patient anxiety
score was higher than the general population both in male (5.4
vs. 4.7) and female (7.7 vs. 5.7). Some associations were found
between the severity of the disease and the depression score (BE
P < 0.004) and (WE P < 0.12) while no association was found
on the anxiety score. The prevalence of severe depression accord-
ing to HADS was 0% in the less severe (BE > = 20/40; WE > =
20/200) but 7.6% in the most severe group (BE < 20/40; WE <
20/200). CONCLUSION: Associations were found between
ARMD and depression and anxiety as measured by the HADS.
The severe depression prevalence rate increases when both eyes
are affected by the disease.
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OBJECTIVE: The control of daily IOP variations is a key driver
of visual ﬁeld protection. IOP is rarely measured during the night
in clinical trials. A model was used to predict nocturnal IOP
peaks from daytime measurements. METHODS: Two clinical
trials documenting IOP every 4 hours over several days were
pooled. Nocturnal IOP peak was deﬁned as the maximum value
observed at midnight and 4 AM and was related to diurnal mea-
sures (taken at 8:00, 12:00, 16:00 and 20:00). We employed
neural networks that included linear, radial basis, and multi-layer
perceptron (MLP) selected to minimize error and take into
account diversity. The probability of a nocturnal IOP peak > 17.5
mmHg was estimated. The neural network model was then
applied to data from a trial comparing timolol, travoprost and
latanoprost over 1 year. Drug comparisons were made using a
mixed linear model. RESULTS: 440 pairs of day and night IOP
measures were identiﬁed. A MLP (2:7:1) model was selected
based on sensitivity and speciﬁcity which were both close to one.
The analysis of the MLP output showed afternoon IOPs were
stronger predictors of night peaks than morning IOPs. Applying
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the MLP to the trial data showed that timolol-treated patients
had a higher risk of developing night IOP peaks than travoprost-
treated patients. The estimates were 57.8% versus 58.2% (P <
0.90) respectively for travoprost and latanoprost using 8:00
IOPs, but 43.6% versus 50.0% (P < 0.05) with 10:00 IOPs, and
43.9% versus 53.3% (P < 0.005) using 16:00 IOPs. CONCLU-
SION: IOP measures during the day are correlated with night
measures. The MLP results suggest that control of IOP in late
afternoon might also prevent night IOP peaks. Prostaglandin
analogues were associated with a lower probability of late after-
noon and night time IOP peaks than timolol. The travoprost
night IOP peak probability was lower than that for latanoprost.
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OBJECTIVE: To conﬁrm randomized clinical trial results
showing that travoprost reduces IOP with sustained efﬁcacy 
in the afternoon, 20–24 hours after the last instillation.
METHODS: Patients treated with a prostaglandin analogue
monotherapy for ocular hypertension or glaucoma was included
in this cross-sectional retrospective survey. Demographics, anam-
nesis, previous treatments were collected from medical chart.
IOP and the last instillation time were collected during the visit.
ANOVA, logistic regressions and propensity scores were used to
compare the 2 treatments. RESULTS: 2503 patients were
included by 494 ophthalmologists. Patients averaged 64 years
old (45% male). 2052 patients were treated with travoprost or
latanoprost and the last instillation time was documented for
1702 of them. 1241 patients had properly used their medication
within the previous day and 461 patients had failed to take it.
IOP was 25mmHg at diagnosis and 22.5mmHg at the initiation
of the current treatment. The two groups were comparable but
travoprost-treated patients had a shorter disease and treatment
duration. When the instillation was given during the day before,
travoprost better controlled IOP at 12.00 and 16.00 hours
(16.79 versus 17.51mmHg; P < 0.05) and after 16.00 (16.55
versus 17.67mmHg; P < 0.003). When the interval time between
the instillation and IOP recordings was >24 hours, travoprost-
treated patients had a lower IOP (16.76 versus 17.80mmHg; P
< 0.002). The percentage of patients reaching the pre-deﬁned
target IOP was higher with travoprost than with latanoprost,
independent of instillation time (81.9% versus 67.3% (P <
0.0001) when intake was the previous day, and 78.5% versus
68.3% (P < 0.03) when intake >24 hours. These differences per-
sisted after adjustment for confounding factors. CONCLUSION:
This observational survey conﬁrmed the previous clinical data
demonstrating that travoprost uniformly controls IOP through
the day with a strong remnant effect, since IOP remains well con-
trolled for more than 24 hours.
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OBJECTIVES: The purpose of this study was to assess the incre-
mental effect on intraocular pressure (IOP) reduction when
changing from latanoprost-timolol ﬁxed combination in the
treatment of primary open-angle glaucoma (POAG).
METHODS: Retrospective analysis was conducted of the
Glasgow Royal Inﬁrmary Glaucoma database. The database was
comprised of computerized medical records of all POAG patients
treated at the Glasgow Royal Inﬁrmary from 1981 to present.
Data elements recorded for each patient included demographics,
diagnosis, and treatment history. Treatment history included
initial and subsequent medication regimens. Patient IOP was
measured before and after treatment change and mean change
with 95% C.I. was calculated. RESULTS: Eighty-three cases of
POAG were identiﬁed where treatment was changed from
evening dosed latanoprost to latanoprost-timolol once daily to
achieve or maintain lower target IOP. The mean incremental
reduction in IOP was 2.01mmHg (95% C.I. 1.22–2.81). 
CONCLUSIONS: In POAG patients treated with latanoprost
who require lower target pressures to control their disease,
latanoprost-timolol ﬁxed combination provides additional incre-
mental IOP reduction. Additional research should be conducted
to further characterize and understand the importance of efﬁcacy
of combination therapy in the treatment of glaucoma.
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OBJECTIVE: To compare the efﬁcacy of latanoprost, bimato-
prost and travoprost for controlling IOP using data published 
in the literature. METHODS: Randomized clinical trials were
identiﬁed on Medline and Embase using the following key
words: glaucoma, ocular hypertension, randomization, trial,
latanoprost, bimatoprost and travoprost. The trials had to
compare at least two prostaglandins head-to-head in monother-
apy. Cross-over experimental designs were excluded. Sample
size, IOP at inclusion and ﬁnal visit, age, gender, race and period
of follow-up were collected. Daily average IOP was estimated
when measurements were available over the study period.
Latanoprost was used as the reference treatment for compar-
isons. Multiple regression analyses estimated the effects of the
different treatments on IOP after controlling for IOP at inclu-
sion and duration of follow-up. All analyses were weighted using
number of patients (inversely proportional to variance weights).
RESULTS: A total of 224 papers were identiﬁed, including 15
randomized clinical trials, which compared two prostaglandin
monotherapies. Six studies were excluded: three cross-over
designs, one with daily intake not in accordance with the SmPC,
one combination study, and one without documented average
IOP. The average age varied from 56.7 to 68.8 years and the IOP
at inclusion from 22.3 to 26.5mmHg. 378 patients were treated
with bimatoprost, 385 with travoprost and 548 with
latanoprost. After adjusting for baseline IOP and period of
follow-up, both patients treated with travoprost and bimato-
prost tended to have a lower IOP (-0.63mmHg [-1.56; 0.30]
and -0.78 mmHg [-1.75; 0.18], respectively) than those treated
with latanoprost. After adjusting for IOP at baseline, follow-up
period, age and gender the treatment effects were -0.72 [-2.02;
0.57] and -0.69 [-2.04; 0.65] for travoprost and bimatoprost,
respectively. CONCLUSION: Based on the information available
in the literature, travoprost and bimatoprost may have greater
